Difficulties in funding of VA-ECMO therapy for patients with severe accidental hypothermia

Sylweriusz Kosiński¹, ², Tomasz Darocha³–⁵, Anna Jarosz⁶, Aleksandra Czerw⁷, Paweł Podsiadło⁵, ⁸, Tomasz Sanak⁹, Robert Gałążkowski⁵, ¹⁰, Jacek Piątek¹¹, Janusz Konstanty-Kalandyk¹¹, Mirosław Ziętkiewicz⁵, Krzysztof Kusza¹², Łukasz J. Krzych⁴, Rafał Drwiła⁶

¹Department of Anaesthesiology and Intensive Care, O. Sokolowski Specialist Hospital of Lung Diseases, Zakopane, Poland
²Tatra Volunteer Rescue Service, Zakopane, Poland
³Department of Anaesthesiology and Intensive Care with Cardiac Monitoring Independent Public Central Clinical Hospital No 7 of the Silesian Medical University in Katowice, Leszek Giec Upper-Silesian Medical Centre, Katowice, Poland
⁴Chair and Department of Anaesthesiology and Intensive Care, Medical University of Silesia in Katowice, Poland
⁵Polish Air Rescue, Warsaw, Poland
⁶Department of Anesthesiology and Intensive Care, Medical College of Jagiellonian University, John Paul II Hospital, Krakow, Poland
⁷Department of Public Health, Medical University of Warsaw, Poland
⁸Polish Society for Mountain Medicine and Rescue, Szczyrk, Poland
⁹Department of Disaster Medicine and Emergency Care, Chair of Anaesthesiology and Intensive Care, Collegium Medicum Jagiellonian University, Krakow, Poland
¹⁰Department of Emergency Medical Service, Medical University of Warsaw, Poland
¹¹Department of Cardiac Surgery, Vascular Surgery and Transplantology, Collegium Medicum, Jagiellonian University, John Paul II Specialist Hospital in Krakow, Poland
¹²Chair and Department of Anaesthesiology and Intensive Care, Poznan University of Medical Sciences, Poznan, Poland

Abstract

Background: Severe accidental hypothermia is defined as a core temperature below 28 Celsius degrees. Within the last years, the issue of accidental hypothermia and accompanying cardiac arrest has been broadly discussed and European Resuscitation Council (ERC) Guidelines underline the importance of Extracorporeal Rewarming (ECR) in treatment of severely hypothermic victims. The study aimed to evaluate the actual costs of ECR with VA-ECMO and of further management in the Intensive Care Unit of patients admitted to the Severe Accidental Hypothermia Centre in Cracow, Poland.

Methods: We carried out the economic analysis of 31 hypothermic adults in stage III-IV (Swiss Staging) treated with VA ECMO. Twenty-nine individuals were further managed in the Intensive Care Unit. The actual treatment costs were evaluated based on current medication, equipment, and dressing pricing. The costs incurred by the John Paul II Hospital were then collated with the National Health Service (NHS) funding, assessed based on current financial contract.

Results: In most of the cases, the actual treatment cost was greater than the funding received by around 10000 PLN per patient. The positive financial balance was achieved in only 4 (14%) individuals; other 25 cases (86%) showed a financial loss.

Conclusion: Performed analysis clearly shows that hospitals undertaking ECR may experience financial loss due to implementation of effective treatment recommended by international guidelines. Thanks to new NHS funding policy since January 2017 such loss can be avoided, what shall encourage hospitals to perform this expensive, yet effective method of treatment.

Key words: membrane oxygenation; severe hypothermia; funding
Hypothermia is defined as a core body temperature (Tc) below 35°C [1]. According to data from the Central Statistical Office, between 2009 and 2012, exposure to excessive natural cold was the initial cause of death of 1,835 people, 489 (27%) of whom died in hospitals [2]. A questionnaire study carried out in 50 emergency departments that provide care for a population of over 4 million individuals revealed that the incidence of accidental hypothermia was 6 cases per 100,000 annually [3].

In several recent years, the issue of therapy for patients with severe stages of hypothermia, including cardiac arrest (stages III and IV according to the Swiss Staging System), has increasingly been disputed in the international literature. In the European Resuscitation Council guidelines, a Tc below 28°C accompanied by haemodynamic instability or cardiac arrest during hypothermia was considered an indication for extracorporeal rewarming (ECR) [4].

The success of medical management depends on the proper identification of patients, the administration of appropriate treatments, the coordination of actions at various levels of care and the availability of effective targeted therapies [5]. Based on the opinions of experts and the guidelines of the European Resuscitation Council, pre-hospital and hospital protocols for the management of patients with hypothermia were created [1, 4, 6]. The protocols enabled the comprehensive and organised use of advanced treatment methods for victims of severe hypothermia, including the initiation of ECR by a mobile team equipped with a portable extracorporeal membrane oxygenation (ECMO) system.

In an effort to meet the challenge of treating severely hypothermic patients, the Severe Accidental Hypothermia Centre (SAHC) was created within the Department of Anaesthesiology and Intensive Care at John Paul II Hospital in Cracow. The Centre treats patients in the same setting according to the same algorithm and by the same team, which provides a unique opportunity to estimate the costs of therapy (which have never been assessed before, according to some authors) and to analyse its cost effectiveness. The data obtained may be relevant for other centres interested in the implementation of ECR for hypothermic patients.

METHODS

The study’s goal was to perform a financial analysis of venous-arterial extracorporeal membrane oxygenation (VA-ECMO) and to determine the general costs of therapy for patients with severe accidental hypothermia receiving intensive care at the Department of Anaesthesiology and Intensive Care in Cracow. The medical records of patients admitted to the Severe Accidental Hypothermia Centre between November 2013 and September 2016 were analysed. The study included 31 adult patients undergoing extracorporeal rewarming whose Tcs ranged from 15.2°C to 29°C. The analysis involved the costs of the implementation of VA-ECMO and of patients’ stays, including laboratory and microbiological tests, imaging examinations and transfusions of blood and blood-derived products. The costs were assessed based on the actual pricing of drugs, equipment and dressing materials purchased by the hospital. The hospital income resulted from funding from the National Health Fund (NFZ), which provided compensation for services classified as medical procedures.

RESULTS

The study group included 17 patients rewarmed during cardiac arrest and 14 patients with cardiogenic shock. The time between cardiac arrest and the initiation of extracorporeal therapy ranged from 107 to 345 minutes. In 2 patients, management was provided by the mobile ECR team.

In the cases of 29 (94%) of the patients, the VA-ECMO system was implanted in the operating suite in the Department of Cardiology and the treatment continued in the Intensive Care Unit (ICU). Two patients died before admission to the ICU — one in the operating suite and one in the Emergency Department at the district hospital. The mean length of stay in the intensive care unit in the Department of Anaesthesiology and Intensive Care was 9 days.

In the group with sudden cardiac arrest (SCA), benefits from the treatment, such as stabilisation of the central temperature and the circulatory and respiratory systems, as well as recovery of consciousness and restitution of the baseline neurological condition, were observed in 8 out of 17 patients (46%). Nine out of 17 patients died (53%). In the group with cardiogenic shock, beneficial effects from the therapy were noted in 8 out of 14 patients (57%); 6 patients in that group (43%) died.

The cumulative analysis of costs is presented in Table 1. The incurred costs in the entire study group were —189,314.99 PLN. The cost of extracorporeal rewarming for each patient exceeded the NHF refund by approximately 10,000.00 PLN. A positive financial balance was achieved in only 4 out of 29 patients who qualified for this therapy (14%). Financial losses were noted for the remaining 25 patients (86%).

DISCUSSION

The collation of costs with incomes revealed financial losses incurred by the service provider for the majority of patients due to the implementation of effective therapy recommended by the international guidelines and the assembly of experts.

Funding for the protocol of management elaborated and implemented in the Severe Accidental Hypothermia Centre is based on cooperation with the Department of Anaesthesiology and Intensive Care and the Department...
### Tabela 1. Cumulative analysis of costs

<table>
<thead>
<tr>
<th>Intensive therapy (PLN)</th>
<th>Cardiac surgery (PLN)</th>
<th>Total cost of stay of 30 patients including drugs and medical procedures (PLN)</th>
<th>Total NHF refund (PLN)</th>
<th>Final (PLN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHF refund</td>
<td>Costs of ECMO implantation and removal</td>
<td>Balance</td>
<td>NHF refund</td>
<td>Costs</td>
</tr>
<tr>
<td>Sum total</td>
<td>648,232.00</td>
<td>541,263.31</td>
<td>106,968.69</td>
<td>674,331.32</td>
</tr>
<tr>
<td>Average per patient</td>
<td>21,607.73</td>
<td>18,042.11</td>
<td>3,565.62</td>
<td>22,477.71</td>
</tr>
</tbody>
</table>

of Cardiac Surgery. The main accounting procedure from the catalogue of services (group code E02 — other cardio-surgical procedures) was listed by the Department of Cardiac Surgery, while the Department of Anaesthesiology and Intensive Care accounted for the treatment of patients based on the TISSS-28. According to the biding regulations, procedure 5.51.01.0005002 could have been performed only by cardiac surgery departments, and its valuation was 404 points. In searching for alternative financing sources that would be adequate for the incurred costs, an attempt was made to consider ECMO therapy an obvious example of treatment for acute cardiopulmonary failure based on the recommendations of the National Supervisory Board and the National Consultant in Anaesthesiology and Intensive Therapy. In such cases, the major criterion for qualification is PaO2/FiO2 < 70 mm Hg at PEEP ≥ 10 cm H2O that does not increase for at least 2 hours despite optimal, conventional ventilation therapy [7]. The time condition cannot be fulfilled in severe hypothermia since extracorporeal rewarming has to be initiated as quickly as possible, and any modifications of the parameters can cause cardiac arrest. Likewise, the interpretation of PaO2/FiO2 in hypothermia is hindered due to cell metabolisms being critically reduced. Out of all of the patients treated, only one (who had concomitant aspiration pneumonia) fulfilled the required criteria.

A positive financial balance following treatment at the Department of Anaesthesiology and Intensive Care, which averaged 5,467.93 PLN, was achieved only for a small percentage of patients. Moreover, it should be stressed that in one case of a patient treated with ECMO by the mobile team in one of the district hospitals (Tc 15.2°C, cardiac arrest), the expenses were not refunded, resulting in the additional loss of 24,680 PLN.

Several years of efforts in medical circles to ensure proper funding for extracorporeal rewarming in hypothermia resulted in the Directive of the Chairman of the National Health Fund No.129/2016/DSOZ on December 30, 2016. According to the Directive, the “ECMO — heart and lung support” procedure, which has a point value of 750, can be refunded in severe hypothermia cases. Accordingly, the centres that gave gone to great lengths to perform extracorporeal therapy in hypothermia ultimately have grounds for refunding the costs of treatment under novel, better conditions. Figure 1 presents the distribution of centres dedicated to ECMO therapy in severely hypothermic victims. The complete list of these centres is available at [www.hipotermia.edu.pl](http://www.hipotermia.edu.pl).

Thanks to numerous educational activities undertaken by the Severe Accidental Hypothermia Centre, the guidelines of National Consultants [8] and advances in knowledge about hypothermia in Polish medical circles, the personnel of first-choice centres for the treatment of severely hypothermic patients will be able to register an increasingly high number of emergency notifications in the near future. Over a period of three years, the coordinators of the Severe Accidental Hypothermia Centre for Extracorporeal Therapy consulted 2005 hypothermic patients.

The use of ECMO in severe hypothermia is a recognised life-saving procedure. This has been confirmed by studies.
from other countries as well as from our Centre [9–12]. However, an adequate model of funding and suitable administrative solutions are relevant factors affecting therapeutic decisions. We hope that the economic aspects of our Centre’s work and the options for extracorporeal rewarming funding presented above will dispel doubts and encourage other centres to implement this treatment method.

CONCLUSIONS
1. The use of venous-arterial ECMO in patients with severe hypothermia can result in financial losses for service providers.
2. The new funding policy introduced recently provides a basis for performing VA-ECMO without causing financial losses for service providers.

ACKNOWLEDGEMENTS
2. Conflict of interest: none.

References:

Corresponding author:
Tomasz Darocha, MD, PhD
Department of Anaesthesiology and Intensive Care with Cardiac Monitoring
Independent Public Central Clinical Hospital No 7 of the Silesian Medical University in Katowice,
Leszek Giec Upper-Silesian Medical Centre
Ziołowa 45/47, 40–635 Katowice
e-mail: tomekdarocha@wp.pl

Received: 5.11.2016
Accepted: 18.03.2017